Furthermore, the combined drug treatment caused 22-fold induced expression of miRNA522-5p, and this miRNA reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5 [91]. The gene discussed is ABCB5; the disease is malignant colon neoplasm.